The Research Council and the R&D community in Norway are planning a new biotechnology research initiative for 2011.

A week before Science|Business brings together experts from Europe to discuss personalised medicine here, we look at what’s happening in the US.

French innovation-focused mutual funds can make tax-efficient equity investments in ExonHit Therapeutics for renewable 3-year periods.

France’s small biopharmaceutical and life science companies have been weakened by the financial crisis and had to face a drastic drop in investment in 2009.

There is still uncertainty among investors about the commercial promise of the emerging field of personalised medicine.